JBS N.V. (JBS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JBS SEC filings page.
JBS N.V. (JBS) reported $86.2B in revenue for fiscal year 2025, up 11.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
JBS’s dominant 2025 mechanic was revenue expansion paired with heavier reinvestment, sharply reducing cash left after capital spending.
The earnings rebound did not translate into equivalent cash: net income reached$2.2B while operating cash flow fell to$2.9B in FY2025. Capital spending increased to$2.1B as inventory reached$6.1B , so reinvestment and working capital absorbed cash even while reported profitability improved.
The balance sheet expanded without a matching increase in leverage. Assets reached
Capital spending rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of JBS N.V.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for JBS N.V., and counted as zero in the overall score.
JBS N.V.'s revenue grew 11.7% year-over-year to $86.2B, a solid pace of expansion. This earns a growth score of 62/100.
JBS N.V. carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
JBS N.V.'s current ratio of 1.60 indicates adequate short-term liquidity, earning a score of 45/100. The company can meet its near-term obligations, though with limited headroom.
While JBS N.V. generated $2.9B in operating cash flow, capex of $2.1B consumed most of it, leaving $832.7M in free cash flow. This results in a low score of 32/100, reflecting heavy capital investment rather than weak cash generation.
Not available for JBS N.V., and counted as zero in the overall score.
JBS N.V. passes 7 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, JBS N.V. generates $1.31 in operating cash flow ($2.9B OCF vs $2.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
JBS N.V. generated $1.1B in free cash flow in Q4 2025, representing cash available after capex. This represents an increase of 8.6% from the same quarter a year earlier.
JBS N.V. held $4.6B in cash against $1.4B in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
JBS N.V. invested $838.3M in capex in Q4 2025, funding long-term assets and infrastructure. This represents an increase of 58.2% from the same quarter a year earlier.
Not reported for Q4 2025.
Not reported for Q4 2025.
JBS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
JBS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|
| Total Assets | $45.2B+11.0% | $44.2B | $40.7B | N/A |
| Current Assets | $18.4B+7.7% | $17.7B | $17.1B | N/A |
| Cash & Equivalents | $4.6B-18.7% | $3.6B-29.8% | $5.6B | $5.1B |
| Inventory | $6.1B+21.8% | $6.6B | $5.0B | N/A |
| Goodwill | $5.9B+8.0% | $5.9B | $5.4B | N/A |
| Total Liabilities | $35.6B+9.5% | $34.7B | $32.6B | N/A |
| Current Liabilities | $11.5B-1.0% | $11.0B | $11.7B | N/A |
| Non-Current Liabilities | $24.1B+15.3% | $23.6B | $20.9B | N/A |
| Long-Term Debt | $1.4B+1.0% | $1.4B | $1.4B | N/A |
| Total Equity | $9.5B+17.1% | $9.5B+0.3% | $8.1B | $9.5B |
| Retained Earnings | N/A | $1.7B | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments.
JBS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|
| Operating Cash Flow | $1.9B+25.7% | N/A | $1.5B | N/A |
| Depreciation & Amortization | $623.7M+12.2% | N/A | $555.9M | N/A |
| Capital Expenditures | $838.3M+58.2% | N/A | $529.7M | N/A |
| Free Cash Flow | $1.1B+8.6% | N/A | $1.0B | N/A |
| Investing Cash Flow | -$853.5M-73.4% | N/A | -$492.1M | N/A |
| Financing Cash Flow | -$38.0M+88.2% | N/A | -$321.0M | N/A |
| Dividends Paid | $0 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.
JBS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| JBS N.V. JBS | FY2025 | $86.2B | $2.2B | 2.6% | $41.4B | 36/100 |
| Kraft Heinz Co KHC | FY2025 | $24.9B | -$5.8B | -23.4% | $29.5B | 39/100 |
| Kellanova K | FY2024 | $12.7B | $1.3B | 10.5% | $29.0B | 49/100 |
| General Mills GIS | FY2026 | $18.4B | -$85.0M | -0.5% | $20.2B | 37/100 |
| Mccormick & Co MKC | FY2025 | $6.8B | $789.4M | 11.5% | $14.0B | 50/100 |
| Hormel Foods Corp HRL | FY2025 | $12.1B | $478.2M | 4.0% | $11.7B | 52/100 |
Where JBS N.V. Ranks
Frequently Asked Questions
What is JBS N.V.'s annual revenue?
JBS N.V. (JBS) reported $86.2B in total revenue for fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is JBS N.V.'s revenue growing?
JBS N.V. (JBS) revenue grew by 11.7% year-over-year, from $77.2B to $86.2B in fiscal year 2025.
Is JBS N.V. profitable?
Yes, JBS N.V. (JBS) reported a net income of $2.2B in fiscal year 2025, with a net profit margin of 2.6%.
How much debt does JBS N.V. have?
As of fiscal year 2025, JBS N.V. (JBS) had $4.6B in cash and equivalents against $1.4B in long-term debt.
What is JBS N.V.'s net profit margin?
JBS N.V. (JBS) had a net profit margin of 2.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is JBS N.V.'s return on equity (ROE)?
JBS N.V. (JBS) has a return on equity of 23.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is JBS N.V.'s free cash flow?
JBS N.V. (JBS) generated $832.7M in free cash flow during fiscal year 2025. This represents a -69.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is JBS N.V.'s operating cash flow?
JBS N.V. (JBS) generated $2.9B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are JBS N.V.'s total assets?
JBS N.V. (JBS) had $45.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are JBS N.V.'s capital expenditures?
JBS N.V. (JBS) invested $2.1B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is JBS N.V.'s current ratio?
JBS N.V. (JBS) had a current ratio of 1.60 as of fiscal year 2025, which is generally considered healthy.
What is JBS N.V.'s debt-to-equity ratio?
JBS N.V. (JBS) had a debt-to-equity ratio of 0.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is JBS N.V.'s return on assets (ROA)?
JBS N.V. (JBS) had a return on assets of 4.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is JBS N.V.'s P/E ratio?
JBS N.V. (JBS) trades at 18.6x earnings, its market capitalization divided by net income of $2.2B net income, FY2025. The market capitalization is $41.4B as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is JBS N.V.'s price-to-sales ratio?
JBS N.V. (JBS) trades at 0.5x sales, its market capitalization divided by revenue of $86.2B revenue, FY2025. The market capitalization is $41.4B as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is JBS N.V.'s Piotroski F-Score?
JBS N.V. (JBS) has a Piotroski F-Score of 7 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are JBS N.V.'s earnings high quality?
JBS N.V. (JBS) has an earnings quality ratio of 1.31x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is JBS N.V.?
JBS N.V. (JBS) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.